Shots: The companies jointly enter into P-I trial evaluating the clinical benefits, combining immune stimulator, Immuntep’s eftilagimod alpha (“efti” or “IMP321”), with Merck and Pfizer’s avelumab. Alliances will jointly develop and commercialize avelumab The Institute of Clinical Cancer Research, will sponsor the trial, conducted & involved under ongoing INSIGHT clinical study evaluating P-II dose of […]Read More
